Number of biosimilar developers growing as costs plummet, say CPhI experts
The biosimilars space is becoming more crowded as new players are attracted by reduced development costs and growing market confidence, according to a panel of experts.
The biosimilars space is becoming more crowded as new players are attracted by reduced development costs and growing market confidence, according to a panel of experts.
Biocon could file up to five biosimilars in Europe and the US by 2017, the Indian drugmaker says as it reports robust second quarter results.
CPhI Worldwide 2015
Piramal chief executive Vivek Sharma won last week’s CPhI award for the pharma industry’s CEO of the year. Outsourcing-Pharma.com spoke to Sharma about his plans for the CDMO the day after the jury’s unanimous decision.
A moving, wireless sensor in bioreactors could “revolutionise” biologics production, say the two Irish institutes which invented the wireless device.